News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

CDK4/6 inhibitors + fulvestrant improve OS in HR-positive, HER2-negative advanced breast cancer
18 Oct 2021
byChristina Lau
The addition of a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor to fulvestrant provides a consistent benefit in overall survival (OS) in patients with hormone receptor (HR)–positive, HER2-negative, advanced or metastatic breast cancer in first-, second- and later-line settings and in most clinicopathological subgroups of interest, results of a US FDA pooled analysis of have shown.
18 Oct 2021

Proteomic profiling of COPD may lead to new treatment strategies
17 Oct 2021
A recent study has provided a detailed proteomic profile that identified proteins associated with the pathogenesis and disease progression of chronic obstructive pulmonary disease (COPD), which can then help in the creation of platform to develop effective new treatment strategies.
17 Oct 2021







